Inipharm 将在 AASLD 的肝脏会议上展示显示 HSD17B13 小分子抑制剂

StephenW

Inipharm 将在 AASLD 的肝脏会议上展示显示 HSD17B13 小分子抑制剂对抗肝纤维化潜力的数据
2021 年 10 月 5 日，星期二，晚上 11:00·2 分钟阅读

华盛顿州贝尔维尤和圣地亚哥，2021 年 10 月 5 日--(美国商业资讯)-- Inipharm 是一家专注于发现和开发肝脏及相关疾病疗法的生物制药公司，今天宣布将提供有关抗纤维化的数据在美国肝病研究协会 (AASLD) The Liver Meeting® 上，其一种 HSD17B13 小分子抑制剂在 NASH 的原代人类细胞“3D 芯片肝脏”模型中的作用几乎是 2021 年 11 月 12 日至 15 日。

“HSD17B13 是一系列严重肝脏疾病（包括 NASH）的重要靶点，因为最近发现该基因的某些变异与这些疾病的肝脏保护密切相关，”首席科学家 Heather Hsu 博士说。 Inipharm 的官员。 “在这些实验中，我们的 HSD17B13 抑制剂 INI-678 在基于人类肝细胞的 3D 肝脏芯片模型中显示纤维化的关键标志物减少，我们认为该模型非常适合反映人类肝脏生理学尊重 HSD17B13。”

摘要标题：有效且选择性的小分子 HSD17B13 抑制剂 INI-678 可改善 NASH 肝脏芯片中的纤维化标志物

出版号：215

会议：口头平行 33：NAFLD 的实验进展

会话广播日期和时间：2021 年 11 月 15 日，星期一，下午 3:00

主要发现：

    与含有库普弗细胞、星状肝细胞的芯片系统中的对照相比，INI-678 处理降低了纤维化标志物 aSMA（35.4±7.5%，p<0.0001）和 1 型胶原蛋白（42.5±6.4%，p<0.0001）细胞和用高脂肪培养基处理的肝细胞。

    INI-678 抑制 HSD17B13 催化的多种底物氧化，具有低 nM 效力。

    INI-678 不抑制测试的 HSD17B 家族的其他成员，也不抑制脱靶面板中的酶和受体。

关于 Inipharm

Inipharm 是一家生物制药公司，专注于发现和开发严重肝病的治疗方法。 Inipharm 的主要项目专注于高度验证的遗传目标 HSD17B13。大量一致的证据表明，HSD17B13 蛋白表达的遗传变异与多种肝脏疾病的发病率和严重程度显着降低有关。 Inipharm 正在推进一系列针对这种蛋白质活性的小分子疗法。

在 businesswire.com 上查看源版本：https://www.businesswire.com/news/home/20211005005420/en/

联系人

卡罗琳·霍利
运河通讯
[email protected]

StephenW

Inipharm to Present Data Showing Potential of Small Molecule Inhibitors of HSD17B13 to Combat Liver Fibrosis at AASLD’s The Liver Meeting
Tue, 5 October 2021, 11:00 pm·2-min read

BELLEVUE, Wash. & SAN DIEGO, October 05, 2021--(BUSINESS WIRE)--Inipharm, a biopharmaceutical company focused on discovering and developing therapies for liver and related diseases, today announced that it will be presenting data on the anti-fibrotic effects of one of its small-molecule inhibitors of HSD17B13 in a primary human cell "3D liver-on-a-chip" model of NASH at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting®, taking place virtually November 12-15, 2021.

"HSD17B13 is a target of great interest for a range of severe liver disorders, including NASH, given recent findings that certain variants of the gene are strongly associated with liver protection in these diseases," said Heather Hsu, Ph.D., chief scientific officer of Inipharm. "In these experiments, our HSD17B13 inhibitor INI-678 showed reduction in key markers of fibrosis in a human liver cell-based 3D liver-on-a-chip model, a model which we believe is well-suited to reflect human liver physiology with respect to HSD17B13."

Abstract Title: Potent and selective small molecule HSD17B13 inhibitor INI-678 improves fibrotic markers in NASH liver-on-a-chip

Publication Number: 215

Session: Oral Parallel 33: Experimental Advances in NAFLD

Session Broadcast Date and Time: Monday, November 15, 2021, 3:00 PM

Key Findings:

    INI-678 treatment decreased fibrosis markers aSMA (35.4±7.5%, p<0.0001) and collagen type 1 (42.5±6.4 %, p<0.0001) compared to control in a liver-on-a-chip system containing Kupffer cells, stellate cells, and hepatocytes treated with high fat media.

    INI-678 inhibits HSD17B13-catalyzed oxidation of multiple substrates with low nM potency.

    INI-678 does not inhibit the other members of the HSD17B family tested nor enzymes and receptors in an off-target panel.

About Inipharm

Inipharm is a biopharmaceutical company focused on discovering and developing therapies for severe liver diseases. Inipharm’s lead programs are focused on the highly validated genetic target, HSD17B13. There is extensive, consistent evidence that genetic variants in expression of HSD17B13 protein are associated with significantly lower rates and severity of multiple liver diseases. Inipharm is advancing a pipeline of small-molecule therapies that target the activity of this protein.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005420/en/

Contacts

Carolyn Hawley
Canale Communications
[email protected]